Climate Change Data

Glaukos Corporation

Climate Impact & Sustainability Data (2022, 2023)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:1929.6 mt
Scope 1 Emissions:569.4 mt
Scope 2 Emissions:1360.2 mt
Renewable Energy Share:40%
Total Energy Consumption:5,681,902 kwh
Water Consumption:1,318,724 gallons
Waste Generated:11,004 lbs
Carbon Intensity:.68 mt/$100,000 of sales

ESG Focus Areas

  • Governance
  • Products
  • Social
  • Environmental

Environmental Achievements

  • Early completion of Greenhouse Gas emission inventory

Social Achievements

  • Launched Glaukos Patient Services (GPS) to improve keratoconus patients’ access to care
  • Introduced the DARE Awards to recognize employees
  • Expanded Glaukos’ global leave policies to provide fully paid disability leave and leave for caretakers
  • Completed new drug manufacturing facility

Governance Achievements

  • 100% of Glaukos users completed cybersecurity training for the second consecutive year.

Climate Goals & Targets

Medium-term Goals:
  • By 2025, formally track alignment of the information security program to relevant components of the NIST security framework based upon the risk to Glaukos and industry best practices
Short-term Goals:
  • Reduce percentage of Glaucoma medical device product transported via air by developing 2nd site distribution center (2021 as baseline)
  • Convert Corneal Health Photrexa cross-linking kits’ packaging and shipment materials to biodegradable materials
  • Based on this year’s Great Place to Work engagement survey results, identify areas of opportunity; communicate and measure progress against improvement areas in the following year
  • Expand ISO 14001 Certification to Burlington site by 2024
  • Create GHG inventory for Scope 1 and 2 GHG emissions data by 2023

Environmental Challenges

  • Maintaining a positive workplace culture in a rapidly growing company.
  • Competition for skilled talent.
  • FDA's unexpected request for a second confirmatory study for Epi-on, delaying submission and approval timelines.
Mitigation Strategies
  • Implementing a People and Talent Strategy, Job Leveling Framework, and various employee engagement initiatives.
  • Utilizing a unique culture, product pipeline, and expanding benefits to attract talent.
  • Commencing subject enrollment in a second Phase 3 confirmatory pivotal trial for Epi-on.

Supply Chain Management

Supplier Audits: Annual audits of critical suppliers; periodic audits of lower-risk suppliers.

Responsible Procurement
  • Supplier Code of Conduct
  • Human and Workforce Rights Policy
  • ESG criteria included in supplier screening questionnaire

Climate-Related Risks & Opportunities

Physical Risks
  • Brush fires
  • Earthquakes

Reporting Standards

Frameworks Used: GRI, SASB

Certifications: ISO 13485, ISO 14001

Sustainable Products & Innovation

  • Biodegradable shipping containers and cold packs (in evaluation)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:2734.8 tCO2e/year (Scope 1 and 2)
Scope 1 Emissions:575.4 tCO2e/year
Scope 2 Emissions:2159.4 tCO2e/year
Renewable Energy Share:58%
Total Energy Consumption:8,865,748 kWh/year
Water Consumption:1,075,624 gallons/year
Waste Generated:15,288 pounds/year (Hazardous)
Carbon Intensity:0.86

ESG Focus Areas

  • Governance
  • Products
  • Social
  • Environmental

Environmental Achievements

  • Reduced emissions associated with flights amounting to a total CO2 GHG emission estimated at 1,286 tons due to a second product distribution site, resulting in reduced shipping costs and elimination of 6.4 million air miles
  • Obtained ISO Certification for Burlington site, signifying our commitment to environmental management system standards

Social Achievements

  • Launched Glaukos World Café, a DEI-related learning session focused on exploring and discussing relevant topics
  • Launched employee student loan reimbursement program
  • Expanded GPS, enrolling nearly 3,000 keratoconus patients and supporting them on their journey to corneal cross-linking treatment
  • Provided approximately $10.5 million in product donations to underserved regions around the world

Governance Achievements

  • Completion of anti-bribery/anti-corruption training by 100% of new or renewing distributors and applicable new hires
  • Annual certification by 100% of employees regarding compliance with Code of Business Conduct and Ethics

Climate Goals & Targets

Medium-term Goals:
  • By 2025, formally track alignment of the information security program to relevant components of the NIST security framework based upon risk to Glaukos and industry best practices
  • By 2030, surpass 10,000 cumulative stent donations and 150 recipient organizations
Short-term Goals:
  • Help >5,000 patients navigate their keratoconus treatment journey by 2024
  • Establish process to make iDose accessible to underserved communities via the iDose Your Dose global program by 2024
  • Provide a comprehensive range of services to U.S. patients and caregivers enrolled through a healthcare provider or self-enrolled to support the critical phase of early decision-making about their keratoconus or glaucoma care by 2025
  • Develop a team of Patient Ambassadors to educate U.S. patient and advocacy organizations by 2027
  • Conduct engineering evaluation of conversion to biodegradable Corneal Health packaging in 2024
  • Update R&D design development documents to require evaluation of sustainability in product design and packaging by 2024
  • By 2027, change from paper IFUs to electronic for all medical devices (where permitted by regulation)

Environmental Challenges

  • Photrexa CXL kits biodegradable packaging unable to maintain regulatorily specified temperatures
Mitigation Strategies
  • Continuing work on finding alternate biodegradable products that meet packaging and transportation requirements for Corneal Health products

Supply Chain Management

Supplier Audits: Annual audits of critical suppliers (Risk level 1); Periodic audits of lower-risk suppliers

Responsible Procurement
  • Supplier Code of Conduct
  • Human and Workforce Rights Policy
  • Risk assessment on all Glaukos suppliers

Climate-Related Risks & Opportunities

Physical Risks
  • Brush fires
  • Earthquakes

Reporting Standards

Frameworks Used: GRI, SASB

Certifications: ISO 13485, ISO 14001

Awards & Recognition

  • Fortune Best Workplace in Biopharma